U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07114315) titled 'A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer' on Aug. 03.
Brief Summary: This is an open-label, multi-center phase II clinical study consisting of two parts:
Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer.
Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Intervention:
DRUG: AK112
Following a predefined dose and date.
DRUG: AK130
Following a predefined...